#1 - Mind Medicine (NASDAQ:MNMD)
Mental health continues to be a growing focus of biotechnology. However, even as more attention is being paid to mental health, there are still few approved treatments That’s where Canadian-based Mind Medicine, Inc. (NASDAQ: MNMD) comes in.
Mind Medicine, or MindMed, is a clinical-stage biotechnology company that is developing therapies and treatments to treat brain health disorders related to psychiatry (ADHD, anxiety, etc.), addiction, pain, and neurology.
Its lead candidate, MM-120, has entered Phase 3 clinical trials for the treatment of Generalized Anxiety Disorder (GAD), which the company notes is a condition that is frequently underdiagnosed. In its January 2025 investor presentation, MindMed announced it was expecting the readout from this trial sometime in the second half of 2026. That’s significant because MindMed is not profitable and is pre-revenue.
About Mind Medicine (MindMed)
Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Read More - Current Price
- $6.76
- Consensus Rating
- Buy
- Ratings Breakdown
- 12 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $26.75 (295.7% Upside)
